JP2025519029A5 - - Google Patents

Info

Publication number
JP2025519029A5
JP2025519029A5 JP2024566284A JP2024566284A JP2025519029A5 JP 2025519029 A5 JP2025519029 A5 JP 2025519029A5 JP 2024566284 A JP2024566284 A JP 2024566284A JP 2024566284 A JP2024566284 A JP 2024566284A JP 2025519029 A5 JP2025519029 A5 JP 2025519029A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
pharmaceutically acceptable
disease
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025519029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/021668 external-priority patent/WO2023220131A2/en
Publication of JP2025519029A publication Critical patent/JP2025519029A/ja
Publication of JP2025519029A5 publication Critical patent/JP2025519029A5/ja
Pending legal-status Critical Current

Links

JP2024566284A 2022-05-10 2023-05-10 PI3Kα阻害剤及びその使用方法 Pending JP2025519029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263364459P 2022-05-10 2022-05-10
US63/364,459 2022-05-10
PCT/US2023/021668 WO2023220131A2 (en) 2022-05-10 2023-05-10 PI3Kα INHIBITORS AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2025519029A JP2025519029A (ja) 2025-06-24
JP2025519029A5 true JP2025519029A5 (cg-RX-API-DMAC10.html) 2026-07-06

Family

ID=88730972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566284A Pending JP2025519029A (ja) 2022-05-10 2023-05-10 PI3Kα阻害剤及びその使用方法

Country Status (14)

Country Link
US (2) US20250313524A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522583A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025519029A (cg-RX-API-DMAC10.html)
KR (1) KR20250024871A (cg-RX-API-DMAC10.html)
CN (1) CN119486992A (cg-RX-API-DMAC10.html)
AR (1) AR129281A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023267583A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251244A1 (cg-RX-API-DMAC10.html)
CL (2) CL2024003398A1 (cg-RX-API-DMAC10.html)
IL (1) IL316619A (cg-RX-API-DMAC10.html)
MX (1) MX2024013762A (cg-RX-API-DMAC10.html)
PE (1) PE20251748A1 (cg-RX-API-DMAC10.html)
TW (1) TW202400175A (cg-RX-API-DMAC10.html)
WO (1) WO2023220131A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021263914B2 (en) 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
EP4598919A1 (en) * 2022-10-07 2025-08-13 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2024199430A1 (zh) * 2023-03-31 2024-10-03 长春金赛药业有限责任公司 PI3Kα抑制剂化合物、药物组合物及其应用
WO2024220876A1 (en) * 2023-04-19 2024-10-24 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
WO2024233256A1 (en) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
KR20260113070A (ko) * 2023-11-15 2026-07-21 릴레이 테라퓨틱스, 인크. PI3Kα 저해제 그리고 이의 제조 방법 및 사용 방법
WO2026041679A1 (en) * 2024-08-22 2026-02-26 F. Hoffmann-La Roche Ag Pyridone carboxamide derived compounds as soluble epoxide hydrolase inhibitors
WO2026092678A1 (zh) * 2024-11-01 2026-05-07 上海翰森生物医药科技有限公司 芳香胺类衍生物抑制剂、其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD145599A1 (de) * 1979-08-23 1980-12-24 Roswitha Toepfer Mittel zur regulierung des pflanzenwachstums
CA2528938A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
PT1940839E (pt) * 2005-10-07 2013-10-10 Exelixis Inc Inibidores de piridopirimidinona pi3k alfa
ZA200904857B (en) * 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
UA98141C2 (ru) * 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2012155199A1 (en) * 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
AU2014331049B2 (en) * 2013-10-04 2018-03-29 Torqur Ag Conformationally restricted PI3K and mTOR inhibitors
CN105503877A (zh) * 2014-09-24 2016-04-20 和记黄埔医药(上海)有限公司 咪唑并哒嗪类化合物及其用途
AR105324A1 (es) * 2015-07-17 2017-09-27 Bayer Cropscience Ag Hidrazidas de ácido carboxílico arilo y heteroarilo cíclicas sustituidas o sus sales y su uso para aumentar la tolerancia al estrés en plantas
MX2020000834A (es) * 2017-08-02 2020-08-20 Univ Tohoku Derivado de adamantilmetilamina y uso del mismo como producto farmaceutico.
SG11202004361SA (en) * 2017-11-13 2020-06-29 Luoxin Pharmaceutical Shanghai Co Ltd Quinazolinone compound and application thereof
CN108864074A (zh) * 2018-06-20 2018-11-23 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
ES3065954T3 (en) * 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
MX2022002282A (es) * 2019-08-28 2022-03-25 Unilever Ip Holdings B V Compuestos novedosos para aclarar la piel.
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
JP2023523402A (ja) * 2020-04-29 2023-06-05 イドーシア ファーマシューティカルズ リミテッド スピロウレア誘導体
AU2021263914B2 (en) * 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
KR20230026404A (ko) * 2020-06-17 2023-02-24 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드
CN113045559B (zh) * 2021-03-15 2022-05-20 贵州医科大学 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CA3217937A1 (en) * 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023014819A (es) * 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2024507131A5 (cg-RX-API-DMAC10.html)
JP2021532162A5 (cg-RX-API-DMAC10.html)
JP2022509260A5 (cg-RX-API-DMAC10.html)
JP2009518296A5 (cg-RX-API-DMAC10.html)
JP2021533135A5 (cg-RX-API-DMAC10.html)
JP2022530989A5 (cg-RX-API-DMAC10.html)
JP2023515888A5 (cg-RX-API-DMAC10.html)
JP2011515482A5 (cg-RX-API-DMAC10.html)
JP2023520916A5 (cg-RX-API-DMAC10.html)
IL301106B2 (en) SHP2 phosphatase inhibitors and methods of using them
JP2006514006A5 (cg-RX-API-DMAC10.html)
JP2010506942A5 (cg-RX-API-DMAC10.html)
JP2022538301A5 (cg-RX-API-DMAC10.html)
JP2013505946A5 (cg-RX-API-DMAC10.html)
CN104530417A (zh) 一种多官能化h型聚乙二醇衍生物及其制备方法
DE69204698T2 (de) Polyaminthiole als Strahlenschutzmittel.
JP2022537140A5 (cg-RX-API-DMAC10.html)
JP2023504542A5 (cg-RX-API-DMAC10.html)
JP2007532627A5 (cg-RX-API-DMAC10.html)
JP2022500499A5 (cg-RX-API-DMAC10.html)
JP2023512206A5 (cg-RX-API-DMAC10.html)
JP2023512227A5 (cg-RX-API-DMAC10.html)
JP2007532625A5 (cg-RX-API-DMAC10.html)
CA2511242A1 (en) Inhibitors of human tumor-expressed ccxckr2
JPS6058747B2 (ja) アミノ化合物の製法